Phase 2 Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2018
Price : $35 *
At a glance
- Drugs Enobosarm (Primary)
- Indications Stress incontinence
- Focus Therapeutic Use
- Sponsors GTx
- 27 Sep 2018 Status changed from recruiting to discontinued due to lack of efficacy
- 11 Jun 2018 Status changed from not yet recruiting to recruiting.
- 14 May 2018 Planned initiation date changed from 30 Apr 2018 to 30 May 2018.